Bin Wu

Dr. Bin Wu

Ocean College, Zhejiang University, Hangzhou 310058, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Fish & Shellfish Immunology
Verified
Journal Article
Closed access
NANajeeb Akhter
Najeeb Akhter
Bin WuBin Wu
Bin Wu
AMAamir Mahmood Memon
Aamir Mahmood Memon
MMMuhammad Mohsin
Muhammad Mohsin

1 July 2021 in Fish & Shellfish Immunology
Verified
Journal Article
Closed access
UBUsman Dawood Butt
Usman Dawood Butt
NLNa Lin
Na Lin
NANajeeb Akhter
Najeeb Akhter
TSTooba Siddiqui
Tooba Siddiqui
SLSihui Li
Sihui Li
Bin WuBin Wu
Bin Wu

10 November 2017 in Marine Drugs
Verified
Journal Article
Open access
PDF file
SSsayed Asmat Ali shah
sayed Asmat Ali shah
NANajeeb Akhter
Najeeb Akhter
BABibi Nazia Auckloo
Bibi Nazia Auckloo
IKISHRAT KHAN
ISHRAT KHAN
YLYanbin Lu
Yanbin Lu
Yue-Wei GuoYue-Wei Guo
Yue-Wei Guo
Nowadays, various drugs on the market are becoming more and more resistant to numerous diseases, thus declining their efficacy for treatment purposes in human beings. Antibiotic resistance is one among the top listed threat around the world which eventually urged the discovery of new potent drugs followed by an increase in the number of deaths caused by cancer due to chemotherapy resistance as well. Accordingly, marine cyanobacteria, being the oldest prokaryotic microorganisms belonging to a monophyletic group, have proven themselves as being able to generate pharmaceutically important natural products. They have long been known to produce distinct and structurally complex secondary metabolites including peptides, polyketides, alkaloids, lipids, and terpenes with potent biological properties and applications. As such, this review will focus on recently published novel compounds isolated from marine cyanobacteria along with their potential bioactivities such as antibacterial, antifungal, anticancer, anti-tuberculosis, immunosuppressive and anti-inflammatory capacities. Moreover, various structural classes, as well as their technological uses will also be discussed.

27 July 2015 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Bin WuBin Wu
Bin Wu
JWJutta Wiese
Jutta Wiese
ALAntje Labes
Antje Labes
AKAnnemarie Kramer
Annemarie Kramer
RSRolf Schmaljohann
Rolf Schmaljohann
JIJohannes Imhoff
Johannes Imhoff
An unusual polyketide with a new carbon skeleton, lindgomycin (1), and the recently described ascosetin (2) were extracted from mycelia and culture broth of different Lindgomycetaceae strains, which were isolated from a sponge of the Kiel Fjord in the Baltic Sea (Germany) and from the Antarctic. Their structures were established by spectroscopic means. In the new polyketide, two distinct domains, a bicyclic hydrocarbon and a tetramic acid, are connected by a bridging carbonyl. The tetramic acid substructure of compound 1 was proved to possess a unique 5-benzylpyrrolidine-2,4-dione unit. The combination of 5-benzylpyrrolidine-2,4-dione of compound 1 in its tetramic acid half and 3-methylbut-3-enoic acid pendant in its decalin half allow the assignment of a new carbon skeleton. The new compound 1 and ascosetin showed antibiotic activities with IC50 value of 5.1 (±0.2) µM and 3.2 (±0.4) μM, respectively, against methicillin-resistant Staphylococcus aureus.

6 March 2014 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Bin WuBin Wu
Bin Wu
VOVanessa Oesker
Vanessa Oesker
JWJutta Wiese
Jutta Wiese
RSRolf Schmaljohann
Rolf Schmaljohann
JIJohannes Imhoff
Johannes Imhoff
Two unusual pyridones, trichodin A (1) and trichodin B (2), together with the known compound, pyridoxatin (3), were extracted from mycelia and culture broth of the marine fungus, Trichoderma sp. strain MF106 isolated from the Greenland Seas. The structures of the new compounds were characterized as an intramolecular cyclization of a pyridine basic backbone with a phenyl group. The structure and relative configuration of the new compounds were established by spectroscopic means. The new compound 1 and the known compound 3 showed antibiotic activities against the clinically relevant microorganism, Staphylococcus epidermidis, with IC50 values of 24 μM and 4 μM, respectively.

1 April 2014 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Bin WuBin Wu
Bin Wu
VOVanessa Oesker
Vanessa Oesker
JWJutta Wiese
Jutta Wiese
SMSusann Malien
Susann Malien
RSRolf Schmaljohann
Rolf Schmaljohann
JIJohannes Imhoff
Johannes Imhoff
A novel spirocyclic drimane coupled by two drimane fragment building blocks 2 and a new drimane 1 were identified in mycelia and culture broth of Stachybotrys sp. MF347. Their structures were established by spectroscopic means. This is the first example of spirocyclic drimane coupled by a spirodihydrobenzofuranlactam unit and a spirodihydroisobenzofuran unit; and the connecting position being N-C instead of an N and N connecting unit. Strain MF347 produced also the known spirocyclic drimanes stachybocin A (12) and stachybocin B (11) featured by two sesquiterpene-spirobenzofuran structural units connected by a lysine residue; the known spirocyclic drimanes chartarlactam O (5); chartarlactam K (6); F1839A (7); stachybotrylactam (8); stachybotramide (9); and 2α-acetoxystachybotrylactam acetate (10); as well as ilicicolin B (13), a known sesquiterpene. The relative configuration of two known spirobenzofuranlactams (3 and 4) was determined. All compounds were subjected to biological activity tests. The spirocyclic drimane 2, 11, and 12, as well as the sesquiterpene 13, exhibited antibacterial activity against the clinically relevant methicillin-resistant Staphylococcus aureus (MRSA).